Introduction The therapeutic use of humanised monoclonal programmed cell death 1 (PD-
1)(pembrolizumab, and nivolumab) and programmed cell death ligand-1 (PD …

Immune checkpoint inhibitors are a new class of oncologic drugs that act via the inhibition of
checkpoints, thereby unlocking the immune system to attack cancer cells. Their emergence …

The introduction of immune checkpoint inhibitors (ICIs) opened a new era in oncologic
therapy. The favourable profile of ICIs in terms of efficacy and safety can be overshadowed …

Therapeutic options for treating advanced melanoma are progressing rapidly. Until six years
ago, the regimen for treating advanced melanoma mainly comprised cytotoxic agents such …

Breakthrough targeted therapies have produced significant improvements in survival for
cancer patients, but have a propensity to cause cutaneous immune‐related adverse events …

Immune checkpoint inhibitors (ICIs) have transformed the treatment of cancer. ICIs enhance
antitumor activity by relieving inhibition of T cells responsible for immune surveillance and …

Immune checkpoint inhibitors (ICIs) represent an emerging treatment option for a variety of
cancer types. Through inhibition of programmed cell death protein 1 (PD-1), programmed …

Background: New oncologic therapies, including immune checkpoint inhibitors (ICIs), have
revolutionized the survival and prognosis of cancer patients. However, these therapies are …

Nivolumab, the programmed cell death 1 inhibitor, is a kind of immune checkpoint inhibitor
commonly used to treat advanced cancers. Unfortunately, such drugs often induce various …

Tumour immunotherapy represented by immune checkpoint inhibitors (ICIs) has greatly
improved the overall prognosis of patients with malignant tumours, and is regarded as an …